Changes in Hypoglycemic Event Characteristics During Use of a Bihormonal Fully Closed-Loop System for Type 1 Diabetes
Diabetes Technology and Obesity Medicine · 2026-01 · 2
DOI: 10.1177/29986702261475723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology and Obesity Medicine, online erschienen am 05.08.2026. Verfasst von Stennie Zoet und 5 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To perform an in-depth analysis of changes in hypoglycemic event characteristics during treatment with a bihormonal fully closed-loop (FCL) system (Inreda AP; Inreda Diabetic, Goor, The Netherlands) compared with prior treatment. Research Design and Methods: One-year data from 25 individuals with type 1 diabetes using an FCL system as their regular treatment were analyzed. The average frequency, severity, duration, depth, and shape of hypoglycemic events (glucose < 3.9 mmol/L for ≥5 min) were calculated from continuous glucose monitoring data and compared with prior therapy.
Results
Mean age was 50.0 (±11.1) years, and 52.0% were male. Prior treatment comprised conventional subcutaneous pumps with intermittent ( n = 12) or continuous ( n = 10) glucose sensors (one of which was a hybrid closed-loop) and multiple daily injections ( n = 3). Mean time in range was 78.6% (±6.4) with FCL treatment versus 58.0% (±16.1) with prior therapy ( P < 0.001). The mean area under the curve of a hypoglycemic event significantly decreased during FCL treatment (23.4 min·mmol/L [±12.2] to 7.7 min·mmol/L [IQR: 7.1–10.0], P < 0.001). Event duration and average event glucose also significantly reduced (duration was 44.1 [±14.2] versus 29.6 [±7.4] min [ P < 0.001], and average glucose level was 3.52 [±0.11] versus 3.63 [±0.04] mmol/L [ P < 0.001]). Overall time below range significantly decreased (2.9% [IQR: 1.1–4.6] to 1.5% [IQR: 0.7–1.8], P = 0.003), while hypoglycemic event frequency remained unchanged (0.9 [±0.6] versus 0.8 [±0.4] per day, P = 0.430).
Conclusions
In a real-world setting, treatment with a bihormonal FCL system leads to long-term improvements in the severity, duration, depth, and shape of hypoglycemic events, accompanied by a reduction in mean glucose levels, thereby contributing to tighter glucose regulation compared with prior conventional therapy.
Zitieren
APA
Zoet, S., Urgert, T., Vlaskamp, L. B., Jansen, T. J., Beijnum, B. F. V., & Laverman, G. D. (2026). Changes in Hypoglycemic Event Characteristics During Use of a Bihormonal Fully Closed-Loop System for Type 1 Diabetes. Diabetes Technology and Obesity Medicine, 2. https://doi.org/10.1177/29986702261475723
Vancouver
Zoet S, Urgert T, Vlaskamp LB, Jansen TJ, Beijnum BFV, Laverman GD. Changes in Hypoglycemic Event Characteristics During Use of a Bihormonal Fully Closed-Loop System for Type 1 Diabetes. Diabetes Technology and Obesity Medicine. 2026;2. doi:10.1177/29986702261475723
BibTeX
@article{Zoet2026,
author = {Zoet, Stennie and Urgert, Thomas and Vlaskamp, Lyan B. and Jansen, Theodorus JP. and Beijnum, Bert-Jan F. van and Laverman, Gozewijn D.},
title = {Changes in Hypoglycemic Event Characteristics During Use of a Bihormonal Fully Closed-Loop System for Type 1 Diabetes},
journal = {Diabetes Technology and Obesity Medicine},
year = {2026},
volume = {2},
doi = {10.1177/29986702261475723}
}
EUVIMED